Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Ribavirin dose modification to reduce hemolysis in liver transplant patients with HCV

Adjusting the dose of ribavirin in liver transplant patients, with some degree of renal dysfunction, reduces the incidence of hemolysis, find researchers from Pittsburgh, Pennsylvania, USA.

News image

fiogf49gjkf04

Many patients develop recurrent hepatitis C virus (HCV), following liver transplantation (LTx).

Although there is no completely satisfactory treatment for recurrent HCV, a combination of interferon-alpha (INF) and ribavirin remains the most widely used.

Ribavirin is eliminated through the kidneys, therefore tends to accumulate in the presence of renal dysfunction.

Hemolysis significantly associated with high serum creatinine and decreased creatinine clearance.
Liver Transplantation

The primary side effect of ribavirin is hemolysis.

In this study, published in the November issue of Liver Transplantation, the research team compared the incidence of hemolysis with renal function in LTx patients with recurrent HCV, who were being treated with ribavirin.

The team examined the incidence of hemolysis and the renal function in 72 patients (58 male, 14 female).

All patients had recurrent HCV, and were receiving INF and ribavirin.

The team grouped the patients according to the percentage decrease of hematocrit, after the introduction of ribavirin.

The patient's baseline serum creatinine and creatinine clearance calculated using the Cockcroft-Gault formula.

Percentage decrease of hematocrit after ribavirin treatment was also compared with creatinine clearance as a continuous variable.

In addition, patients were analyzed in three groups: creatinine clearance of ≥70 ml per min (group A), creatinine clearance <70 ml per min and ≥40 ml per min (group B), and creatinine clearance <40 ml per min (group C).

The research team found that 63% of patients experienced a significant decrease (≥15%) in hematocrit after starting INF and ribavirin.

The mean serum creatinine was 1 mg/dl in this group, and the mean calculated creatinine clearance was 71 ml/min.

However, in the 27 patients, who did not show a significant decrease in hematocrit, the mean serum creatinine was 1 mg/dl, and the mean creatinine clearance was 95 ml/min.

On continuous variable of calculated creatinine clearance, the trend was a decrease in hematocrit following ribavirin treatment, compared with pretreatment.

The team found that the rate of hemolysis was significantly different in group A (54%), group B (71%), and group C (100%).

They found the incidence of hemolysis was significantly associated with higher serum creatinine and decreased creatinine clearance.

Dr Ashok Jain's team concluded, "Because ribavirin is eliminated by the kidneys, this observation points to the need for adjustments in the dose of this agent in LTx patients, who tend to have some degree of renal dysfunction, to reduce the incidence of hemolysis".

"Further pharmacokinetic studies of ribavirin in LTx patients with varying degrees of renal function may allow the development of an algorithm for the safer use of ribavirin in HCV-positive LTx patients".

Liver Transpl 2002; 8: 1007-13
12 November 2002

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us